切换至 "中华医学电子期刊资源库"
高级检索
中华眼科医学杂志(电子版)

中华眼科医学杂志(电子版) ›› 2020, Vol. 10 ›› Issue (03) : 177 -182. doi: 10.3877/cma.j.issn.2095-2007.2020.03.009

综述

泪腺腺样囊性癌相关分子机制的研究进展
柳睿1, 马建民2,†()   
  1. 1. 100730　首都医科大学附属北京同仁医院2018级硕士研究生
    2. 100730　首都医科大学附属北京同仁医院　北京同仁眼科中心　北京市眼科研究所　眼科学与视觉科学北京市重点实验室
  • 收稿日期:2020-02-02 出版日期:2020-06-28
  • 通信作者: 马建民
  • 基金资助:
    北京市医院管理中心"登峰"计划专项基金项目(DFL20190201)

Advances in the molecular mechanisms of lacrimal glandadenoid cystic carcinoma

Rui Liu1, Jianmin Ma2,†()   

  1. 1. Master′s degree 2018, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China
    2. Beijing Tongren Eye Center, Beijing Tongren hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing 100730, China
  • Received:2020-02-02 Published:2020-06-28
  • Corresponding author: Jianmin Ma
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

柳睿, 马建民. 泪腺腺样囊性癌相关分子机制的研究进展[J]. 中华眼科医学杂志(电子版), 2020, 10(03): 177-182.

Rui Liu, Jianmin Ma. Advances in the molecular mechanisms of lacrimal glandadenoid cystic carcinoma[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2020, 10(03): 177-182.

泪腺腺样囊性癌(LGACC)是泪腺最常见的恶性上皮性肿瘤，具有复发率高和早期易发生远处转移的特点。近年来，有关LGACC分子机制的研究取得了一些进展。本文中笔者通过检索国内外有关腺样囊性癌生物学行为分子机制的相关文献，分别从其发生机制、侵袭转移机制与嗜神经性生长机制等方面进行综述，为进一步研究LGACC的分子机制奠定理论基础。

关键词: 腺样囊性癌, 泪腺, 分子机制

Lacrimal gland adenoid cystic carcinoma (LGACC) is the most common malignant epithelial tumor of the lacrimal gland, characterized by high recurrence rate and distant metastasis early. In recent years, progress has been made on the the research of molecular mechanism of LAGCC. In this paper, literatures on the biological and behavioral molecular mechanisms of adenoid cystic carcinoma at home and abroad were summarized from the aspects of its occurrence mechanism, invasion and metastasis mechanism and neurotropic growth mechanism, so as to lay a theoretical foundation for further research on the molecular mechanisms of LGACC.

Key words: Adenoid cystic carcinoma, Lacrimal gland, Molecular mechanism
图1 光学显微镜下泪腺良性淋巴上皮病变动物模型荷瘤的显微结构图(苏木精-伊红染色)　图A示瘤细胞呈实性团块排列，提示病理分型为实性型(×100)；图B示癌巢内有大小不等的筛孔状囊样腔隙，多由肌上皮细胞围绕，提示病理分型为筛状型(×100)
表1 与ACC发生发展、转移侵袭和嗜神经生长有关的生物学指标和信号通路
分类 第一作者 发表年份 相关分子/信号通路 作用效应
发生机制 Bell[5] 2013 多癌基因-人类核因子Ⅰ融合基因 促进
  Li[33] 2017 p53基因 促进
  Branco[22] 2018 B细胞淋巴瘤因子-2基因-核因子κB信号通路和蛋白激酶B信号通路 促进
  Xie[32] 2020 带有YRPW基序1的hes相关家族bHLH转录因子-Notch信号通路 促进
  马赛[35] 2020 癌胚抗原相关细胞黏附分子6 促进
侵袭转移机制 Sun[38] 2012 金属基质蛋白酶家族信号通路 促进
Zhang[37] 2013
  Liu[53] 2013 miRNA-155和表皮生长因子受体-核因子κB途径 上调促进
  Park[48] 2016 血管内皮生长因子 促进
  Huang[55] 2016 1，25-二羟基维生素D3和核因子κB-人谷胱甘肽过氧化物酶-1-激酶型纤溶酶原激活剂途径 抑制
  Xu[56] 2016 Ⅲ型转化生长因子β-核因子κB信号 抑制
  Zhang[58] 2016 miRNA-24-3p和p53-p21信号通路 下调抑制
  曾威[60] 2016 miRNA-582-5p和叉头框蛋白C1基因 上调抑制
  鲍合刚[41] 2017 低氧诱导因子-1α 促进
  张志利[62] 2017 组蛋白去甲基化酶KDM5B和蛋白激酶B信号通路 上调促进
  Yao[54] 2018 胰岛素样生长因子结合蛋白2和核因子κB-E盒结合锌指蛋白1信号通路 促进
  Hao[59] 2018 miRNA-93-5p和Wnt信号通路 下调促进
  Wang[61] 2018 miRNA-21 上调促进
  Qiao[52] 2019 miRNA-140-5p和生存素survivin 下调促进
  Gao[65] 2019 核受体亚族2F组成员1和趋化因子(CXCL12)及其受体(CXCR4)途径 促进
  Xu[64] 2020 ras同源物基因家族成员G-Ras相关的C3肉毒素底物1信号通路 促进
  Jiang[66] 2020 同源框蛋白1-过氧化物酶体增殖物激活受体γ2-游离脂肪酸信号通路 促进
嗜神经生长机制 马晓周[69] 2018 CC趋化因子受体CCR6 促进
  郭佳[73] 2019 施万细胞和NT-3-酪氨酸激酶C信号通路 促进
[1]
Friedrich RE, Bleckmann V. Adenoid cystic carcinoma of salivary and lacrimal gland origin: localization, classification, clinical pathological correlation, treatment results and long-term follow-up control in 84 patients[J]. Anticancer Res, 2003, 23(2A): 931-940.
[2]
Sanders JC, Mendenhall WM, Werning JW. Adenoid cystic carcinoma of the lacrimal gland[J]. Am J Otolaryngol, 2016, 37(2): 144.
[3]
Zhang M, Fathy C, Breazzano MP, et al. Intra-arterial Chemotherapy for Lacrimal Gland Adenoid Cystic Carcinoma[J]. International ophthalmology clinics, 2017, 51(3): 143-152.
[4]
Von Holstein S, Rasmussen PK, Heegaard S. Tumors of the lacrimal gland[J]. Semin Diagn Pathol, 2016, 33(3): 156.
[5]
Bell D, Hanna EY. Head and neck adenoid cysticcarcinoma: What is new in biological markers and treatment[J]. Otolaryngol Head & Neck Surg, 2013, 21(2): 124-129.
[6]
Persson M, Andrén Y, Mark J, et al. Recurrentfusionof MYB and NFIB transcription factor genes in carcinomas of the breast andhead and neck[J]. Proc Natl AcadSci USA, 2009, 106(44): 18740-18744.
[7]
Mitani Y, Li J, Rao PH, et al. Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: Incidence, variability, and clinic opathologic significance[J]. ClinCancer Res, 2010, 16(19): 4722-4731.
[8]
Stenman G. Fusion oncogenes in salivary gland tumors: Molecularand clinical consequences[J]. Head Neck Pathol, 2013, 7(S1): S12-S19.
[9]
Chen TY, Keeney MG, Chintakuntlawar AV, et al. Adenoid cysticcarcinoma of thelacrimal gland isfrequentlycharacterized by MYBrearrangement[J]. Eye, 2017, 31(5): 720-725.
[10]
von Holstein SL, Fehr A, Persson M, et al. Adenoid cystic carcinoma of the lacrimal gland: MYB gene activation, genomic imbalances, and clinical characteristics[J]. Ophthalmology, 2013, 120(10): 2130-2138.
[11]
Stenman G, Andersson MK, Andren Y. New tricks from an old oncogene: Gene fusion and copy number alterations of MYB in humancancer[J]. Cell Cycle, 2010, 9(15): 2986-2995.
[12]
Yasmin D, Sara F, Bruno A, et al. Frequency and prognostic importance of translocation (6：9) (MYB-NFIB Genes) in head and neck adenoid cystic carcinoma: a systematic review[J]. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2020，129(1): e147.
[13]
Wetterskog D, Wilkerson PM, Rodrigues DN, et al. Mutation profiling of adenoid cystic carcinomas from multiple anatomical sites identifies mutations in the RAS pathway，but no KIT mutations[J]. Histopathology, 2013, 62(4): 543-550.
[14]
Stenman G, Persson F, Andersson MK. Diagnosticand therapeutic implications of new molecular biomarkers in salicary gland cancer[J]. Oral Oncol, 2014, 50(8): 683-690.
[15]
Dillon P, Moskaluk C, Fracasso P, et al. Phase Ⅱ study of dovitinib (TKI258) in patients with progressive metastatic adenoid cysticcarcinoma[J]. J Clin Oncol, 2013, 20(11): 31-42.
[16]
Frierson HF, Moskaluk CA. Mutation signature of adenoid cysticcarcinoma: Evidence for transcriptional and epigenetic reprogramming[J]. J Clin Invest, 2013, 123(7): 2783-2785.
[17]
Ivanov SV, Panaccione A, Brown B, et al. TrkC signaling is activated in adenoid cystic carcinoma and requires NT-3 to stimulateinvasive behavior[J]. Oncogene, 2013, 32(32): 3698-3710.
[18]
Frerich CA, Sedam HN, Kang H, et al. N-Terminal Truncated Myb with New Transcriptional Activity Produced Through Use of an Alternative MYB Promoter in Salivary Gland Adenoid Cystic Carcinoma[J]. Cancers (Basel), 2019, 12(1): E45.
[19]
Andersson MK, Åman P, Stenman G. IGF2/IGF1R Signaling as a Therapeutic Target in MYB-Positive Adenoid Cystic Carcinomas and Other Fusion Gene-Driven Tumors[J]. Cells, 2019, 8(8): E913.
[20]
Pham T, Pereira L, Roth S, et al. First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427) [J]．Contemp Clin Trials Commun, 2019, 16: 100409.
[21]
Crittenden MR, Cottam B, Savage T, et al. Expression of NF-kappaB p50 in tumor stroma limits the control of tumors by radiationtherapy[J]. PLoS One, 2012, 7(6): e39295.
[22]
Branco KFCC, Ribeiro ALR, de Mendonça RP, et al. Abnormal activation of the Akt signaling pathway in adenoid cystic carcinoma[J]. Eur Arch Otorhinolaryngol, 2018, 275(12): 3039-3047.
[23]
Zhang J, Peng B. In Vitro Angiogenesis and Expression of Nuclear Factor KappaB and VEGF in High and Low Metastasis Cell Lines of Salivary Gland Adenoid Cystic Carcinoma[J]. BMC Cancer, 2007, 7: 95.
[24]
Wang XF, Wu DM, Li BX, et al. Synergistic inhibitory effect ofsulforaphane and 5- fluorouracil in high and low metastasis celllines of salivary gland adenoid cystic carcinoma[J]. PhytotherRes, 2009, 23(3): 303-307.
[25]
郭素珍，宋国祥，王炳亮. 泪腺肿瘤中bcl-2表达的意义[J]. 中国肿瘤临床，1998，25(123):905.
[26]
Lobry C, Oh P, Aifantis I. Oncogenic and tumor suppressorfunctions of Notch in cancer: it's NOTCH what you think[J]. J Exp Med, 2011, 208(10):1931-1935.
[27]
Liu L, Hu Y, Fu J, et al. MicroRNA155 in the growth and invasion of salivary adenoid cystic carcinoma[J]. J Oral Pathol Med, 2013, 42(2): 140-147.
[28]
Even C, Lassen U, Merchan J, et al. Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase Ⅰ trial expansion cohort of advanced or metastatic adenoid cystic carcinoma[J]. Invest New Drugs, 2020, 38(2): 402-409.
[29]
Sant DW, Tao W, Field MG, et al. Whole exome sequencing of lacrimal gland adenoid cystic carcinoma[J]. Invest Ophthalmol Vis Sci, 2017, 58(6): BIO240-BIO246.
[30]
Sajed DP, Faquin WC, Carey C, et al. Diffuse staining for activated NOTCH1 correlates with NOTCH1 mutation status and isassociated with worse outcome in adenoid cystic carcinoma[J]. AmJ Surg Pathol, 2017, 41(11): 1473-1482.
[31]
彭彩霞，王晓峰，王聪. p53抑癌基因在腺样囊性癌中的作用[J]. 现代肿瘤医学，2016，24(6):1014-1016.
[32]
Xie J, Lin LS, Huang XY, et al. The NOTCH1-HEY1 pathway regulates self-renewal and epithelial-mesenchymal transition of salivary adenoid cystic carcinoma cells[J]. Int J Biol Sci, 2020, 16(4): 598-610.
[33]
Li Q, Huang P, Zheng C, et al. Prognostic significance of p53 immunohistochemical expression in adenoid cystic carcinoma of the salivary glands: a meta-analysis[J]. Oncotarget, 2017, 8(17): 29458-29473.
[34]
Qiu L, Liu Z, Wu CZ, et al. C6-ceramide induces salivary adenoid cystic carcinoma cell apoptosis via IP3R-activated UPR and UPR-independent pathways[J]. Biochemical and Biophysical Research Communications, 2020, 525(4): 997-1003.
[35]
马赛，安峰，李立恒，等. CEACAM6在涎腺原发性腺样囊性癌中的表达及对肿瘤增殖的影响[J]. 川北医学院学报，2020，35(1):31-34.
[36]
Xu L, Li L, Zhang J, et al. Accumulated cytotoxicity of CDK inhibitor dinaciclib with first-line chemotherapy drugs in salivary adenoid cystic carcinoma cells[J]. Odontology, 2020, 108(2): 300-311.
[37]
Zhang L, Zhang H, Song GX, et al. The expression of MMP-2 and MMP-9 in adenoid cystic carcinoma of lacrimal gland[J]. Chin J Ophthalmol, 2013, 49(1): 58-63.
[38]
Sun J, Yu YC, Luo YX, et al. Expression of erythroblastic leukemia viral oncogene homolog 3 (ErbB-3) binding protein-1, matrix metalloproteinases, eplthelial cadherin in adenoid cystic carcinoma and correlation analysis[J]. Cancer, 2012, 47(12): 711-714.
[39]
Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascularendothelial growth factor gene transcription by hypoxia-inducible factor 1[J]. Mol Cell Biol, 1996, 16(9): 4604-4613.
[40]
Fan C, Tu C, Qi P, et al. GPC6 promotes cell proliferation，migration, and Invasion in nasopharyngeal carcinoma[J]. J Cancer, 2019, 10(17): 3926-3932.
[41]
鲍合刚，肖亮，孟刚，等. 涎腺腺样囊性癌中HIF-1α和BCL-2的表达及意义[J]. 临床与实验病理学杂志，2017，33(7):728-731.
[42]
王敬. 涎腺腺样囊性癌中MTA1、HIF-1α的表达及临床意义[D]. 武汉：华中科技大学，2013.
[43]
Zhanwei C, Dubin S, Shengyun H, et al. Analysis of BNIP3 expression and clinical research in salivary adenoid cystic carcinoma[J]. Hua Xi Kou Qiang Yi Xue Za Zhi, 2016, 34(4): 404-407.
[44]
Wang YF, Ma SR, Wang WM, et al. Inhibition of survivin reduces HIF-1α，TGF-β1 and TFE3 in salivary adenoid cystic carcinoma[J]. PLoS One, 2014, 9(12): e114051.
[45]
孙巧妹，林宇静. HIF-1α在唾液腺腺样囊性癌中的表达及临床意义[J]. 中外医学研究，2015，13(3):7-8.
[46]
刘佳，张美琴，于明岳，等. 唾液腺腺样囊性癌侵袭转移的研究进展[J]. 中国实验诊断学，2019，23(11):2040-2043.
[47]
Ni Q, Sun J, Ma C, et al. The Neuropilins and Their Ligands in Hematogenous Metastasis of Salivary Adenoid Cystic Carcinoma-An Immunohistochemical Study[J]. J Oral Maxillofac Surg, 2018, 76(3): 569-579.
[48]
Park S, Nam SJ, Keam B, et al. VEGF and Ki-67 Overexpression in Predicting Poor Overall Survival in Adenoid Cystic Carcinoma[J]. Cancer Res Treat, 2016, 48(2): 518-526.
[49]
Stenner M, Demgensky A, Molls C, et al. Prognostic value of survivin expression in parotid gland cancer in consideration of different histological subtypes[J]. European J Cancer, 2011, 47(7): 1013-1020.
[50]
Mulay K, Puthyapurayil FM, Mohammad JA, et al. Adenoid cysticcarcinoma of the lacrimal gland: Role of nuclear surviving(BIRC5) as a prognostic marker[J]. Histopathology, 2013, 62(6): 840-846.
[51]
富凯，杨军，汪欣，等. Survivin siRNA抑制人腺样囊性癌ACC-2细胞移植瘤血管生成[J]. 第三军医大学学报，2010，32(16):1750-1753.
[52]
Qiao Z, Zou Y, Zhao H. MicroRNA-140-5p inhibits salivary adenoid cystic carcinoma progression and metastasis via targeting surviving[J]. Cancer Cell Int, 2019，19(1): 301.
[53]
Liu L, Hu Y, Fu J, et al. MicroRNA155 in the growth and invasion of salivary adenoid cystic carcinoma[J]. J Oral Pathol Med, 2013, 42(2): 140-147.
[54]
Yao X, Wang Y, Duan Y, et al. IGFBP2 promotes salivary adenoid cystic carcinoma metastasis by activating the NF-κB/ZEB1 signaling pathway[J]. Cancer Lett, 2018, 432: 38-46.
[55]
Huang Z, Liu Y, Huang Z, et al. 1，25-Dihydroxyvitamin D3 alleviates salivary adenoid cystic carcinoma progression by suppressing GPX1 expression through the NF-κB pathway[J]. Int J Oncol, 2016, 48(3): 1271-1279.
[56]
Xu D, Li D, Lu Z, et al. Type Ⅲ TGF-β receptor inhibits cell proliferation and migration in salivary glands adenoid cystic carcinoma by suppressing NF-κB signaling[J]. Oncol Rep, 2016, 35(1): 267-274.
[57]
Serocki M, Bartoszewska S, Janaszak-Jasiecka A, et al. miRNAs regulate the HIF switch during hypoxia: a novel therapeutic target[J]. Angiogenesis, 2018, 21(2): 183-202.
[58]
Zhang MX, Zhang J, Zhang H, et al. miR-24-3p Suppresses Malignant Behavior ofLacrimal Adenoid Cystic Carcinoma byTargeting PRKCH to Regulate p53/p21 Pathway[J]. PLoS One, 2016, 11(6): e0158433.
[59]
Hao J, Jin X, Shi Y, et al. miR-93-5p enhance lacrimal glandadenoid cystic carcinoma cell tumorigenesisby targeting BRMS1L[J]. Cancer Cell Int, 2018，18(1): 72-84.
[60]
曾威，卢文辉，张志利，等. miR-582-5p在唾液腺腺样囊性癌侵袭、转移中的作用[J]. 中国口腔颌面外科杂志，2016，14(5):413-418.
[61]
Wang C, Li T, Yan F, et al. Effect of simvastatin and microRNA-21 inhibitor on metastasis and progression of human salivary adenoid cystic carcinoma[J]. Biomed Pharmacother, 2018, 105: 1054-1061.
[62]
张志利，卢文辉，曾威，等. KDM5B在唾液腺腺样囊性癌侵袭与转移中的作用[J]. 中国口腔颌面外科杂志，2017，15(1):16-19.
[63]
马宇歌. 阻断PI3K信号通路以控制唾液腺腺样囊性癌发展和转移的机制研究[C]. 昆明：第十三次全国口腔病理学术会议论文集，2019：6.
[64]
Xu ZD, Hao T, Gan YH. RhoG/Rac1 signaling pathway involved in migration and invasion of salivary adenoid cystic carcinoma cells[J]. Oral Dis, 2020, 26(2): 302-312.
[65]
Gao XL, Zheng M, Wang HF, et al. NR2F1 contributes to cancer cell dormancy, invasion and metastasis of salivary adenoid cystic carcinoma by activating CXCL12/ CXCR4 pathway[J]. BMC Cancer, 2019, 19(1): 743-754.
[66]
Jiang YP, Tang YL, Wang SS, et al. PRRX1-induced epithelial-to-mesenchymal transition in salivary adenoid cystic carcinoma activates the metabolic reprogramming of free fatty acids to promote invasion and metastasis[J]. Cell Prolif, 2020, 53(1): e12705.
[67]
陈桂军，丁素玲. 泪腺腺样囊性癌嗜神经侵袭生长机制的免疫组化探讨[J]. 中国现代药物应用，2015，9(10):1-3.
[68]
王磊峰，董玉萍，朱素芳，等. 泪腺腺样囊性癌S-100蛋白、神经细丝酸性蛋白的表达及其意义[J]. 武警医学，2014，25(12):1252-1255.
[69]
马晓周，刘麒麟，尹唯凰，等. CC趋化因子受体6在人唾液腺腺样囊性癌组织中的表达及其临床意义[J]. 吉林大学学报(医学版)，2018，44(1):147-150.
[70]
柏书博，李力，陈贵敏. 涎腺腺样囊性癌发生发展相关基因研究进展[J]. 临床军医杂志，2017，45(1):104-107.
[71]
应重华，李蜀光，何凯辉. 神经生长因子在涎腺腺样囊性癌中的研究进展[J]. 包头医学院学报，2018，34(4):130-132.
[72]
李欢，杨新杰，王维戚，等. 应用RNA-Seq技术筛选唾液腺腺样囊性癌嗜神经侵袭相关差异表达基因[J]. 中国口腔颌面外科杂志，2018，16(3):114-119.
[73]
郭佳，李欢，王珺等. 施万细胞通过NT-3/TrkC信号通路促进SACC嗜神经侵袭的研究[J]. 实用口腔医学杂志，2019，35(2):176-180.
[74]
张美，梁新华，汤亚玲. 涎腺腺样囊性癌嗜神经侵袭分子机制的研究进展[J]. 华西口腔医学杂志，2018，36(2):204-211.
[1] 李丁昌, 曹李, 陈鹏, 董光龙. 结直肠癌肝转移多阶段机制研究进展[J]. 中华普外科手术学杂志(电子版), 2021, 15(06): 696-699.
[2] 葛晓东, 龚明福, 白奇之, 赵刚, 甘慧, 戴书华. MSCT对原发性气管支气管腺样囊性癌的12例诊断及文献复习[J]. 中华肺部疾病杂志(电子版), 2022, 15(03): 344-348.
[3] 刘晓梅, 张露, 刘旭, 梁蝶. 巨噬细胞迁移抑制因子靶向miR-127-3p对人肾癌细胞生物学行为的影响[J]. 中华细胞与干细胞杂志(电子版), 2023, 13(02): 76-83.
[4] 李卓林, 贾如雪, 吴亚婷, 张胜行, 王水良. 肿瘤转移的分子机制及靶向干预研究新进展[J]. 中华细胞与干细胞杂志(电子版), 2022, 12(01): 51-58.
[5] 张梦圆, 刘晋灵, 王彤, 张宝林. 黑色素母细胞沿神经的迁移[J]. 中华细胞与干细胞杂志(电子版), 2021, 11(01): 48-50.
[6] 曹润峰, 葛俊文, 方霞, 沈立. 间充质干细胞源性外泌体microRNA在心脏缺血性损伤修复中的研究进展[J]. 中华细胞与干细胞杂志(电子版), 2021, 11(01): 40-47.
[7] 曹冰, 张晓明, 梁富龙. 单细胞测序分析人类胚胎干细胞神经分化的分子机制[J]. 中华细胞与干细胞杂志(电子版), 2021, 11(01): 1-7.
[8] 胡明泰, 郑玉廷, 谢峰. 胆囊癌病因及分子机制研究进展[J]. 中华肝脏外科手术学电子杂志, 2021, 10(02): 224-226.
[9] 金玺, 孙康, 郭建, 孔梅. 结直肠癌肝转移发生机制的研究进展[J]. 中华结直肠疾病电子杂志, 2023, 12(02): 163-166.
[10] 姜金玉, 张东蕾, 何伟. 蓝光照射氧化损伤模型在眼部疾病中应用的研究进展[J]. 中华眼科医学杂志(电子版), 2022, 12(03): 168-172.
[11] 李坚, 陶勇, 郦舒伊, 张小花, 胡勇平. 细胞因子与眼科疾病的研究进展[J]. 中华眼科医学杂志(电子版), 2022, 12(02): 115-119.
[12] 赵梓妍, 丁怡, 马建民. 雌激素缺乏对泪腺组织影响的研究进展[J]. 中华眼科医学杂志(电子版), 2021, 11(04): 252-256.
[13] 柳睿, 王楠, 王金锦, 孙梅, 葛心, 马建民. 免疫球蛋白4相关性泪腺炎和泪腺淋巴瘤患者临床特征及免疫学指标差异性分析的临床研究[J]. 中华眼科医学杂志(电子版), 2021, 11(04): 217-222.
[14] 柳睿, 马建民. 缺氧诱导因子-1α和血管内皮生长因子在泪腺腺样囊性癌中表达及其作用机制的研究现状[J]. 中华眼科医学杂志(电子版), 2020, 10(05): 306-310.
[15] 柯杨. 食管鳞癌精准防治基础研究概述[J]. 中华临床医师杂志(电子版), 2021, 15(01): 1-9.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号